Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and Safety of Combination EMB-001 as a Potential Smoking Cessation Treatment

Next Previous
X
Search
Trial Profile

Efficacy and Safety of Combination EMB-001 as a Potential Smoking Cessation Treatment

Status: Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 05 May 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Metyrapone/oxazepam (Primary)
  • Indications Smoking withdrawal
  • Focus Therapeutic Use

    • Most Recent Events

    • 30 Jun 2021 According to an Embera NeuroTherapeutics media release, the first subject has been dosed in this Phase 2a study, also the company expects to report topline results in Q1 2022.
    • 26 May 2021 Status changed from not yet recruiting to recruiting.
    • 27 Apr 2021 Status changed from planning to not yet recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top